Research Article| Volume 17, ISSUE 1, P82-87, January 1995

Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia

      This paper is only available as a PDF. To read, Please Download here.


      Seventy-nine patients with benign prostatic hyperplasia (BPH) were treated with cernitin pollen extract. Patient ages ranged from 62 to 89 years (mean, 68 years). Mean baseline prostatic volume was 33.2 cm3. Cernitin pollen extract was administered in a dosage of 126 mg (2 tablets, 63 mg each), three times a day, for more than 12 weeks. Symptom scores, based on a modified Boyarsky scoring scale, uroflowmetry, prostatic volume, residual urine volume, and urinalysis results were examined before and after administration of cernitin pollen extract. Symptom scores significantly decreased from baseline, and the favorable results continued during the treatment period. Urine maximum flow rate and average flow rate increased significantly from 9.3 mL/s to 11 mL/s and from 5.1 mL/s to 6 mL/s, respectively. Residual urine volume decreased significantly from 54.2 mL to less than 30 mL. There was no change in prostatic volume. However, 28 patients treated for more than 1 year showed a mean decrease of prostatic volume to 26.5 cm3. No adverse reactions were observed. Clinical efficacy at 12 weeks was rated excellent, good, satisfactory, and poor in 11%, 39%, 35%, and 15% of patients, respectively. Overall clinical efficacy was 85%. In conclusion, cernitin pollen extract showed a mild beneficial effect on prostatic volume and urination variables in patients with symptomatic BPH.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ito R
        • Noguchi K
        • Yamashita S
        • et al.
        Anti-inflammatory effects of cernitin pollen-extract (Cernilton).
        Pharmacometrics. 1984; 28: 55-65
        • Nakaarai K
        • Sonoda T
        Effect of the prostatic extract (Robaveron) on bladder function: An experimental study.
        Acta Urol Jpn. 1972; 18: 501-515
        • Kimura M
        • Kimura I
        • Nakase K
        • et al.
        Micturition activity of pollen extract: Contractile effects on bladder and inhibitory effects on urethral smooth muscle of mouse and pig.
        Planta Med. 1986; 2: 148-151
        • Habib FK
        • Ross M
        • Buck AC
        • et al.
        In vitro evaluation of the pollen extract, Cernitin T-60, in the regulation of prostate cell growth.
        Br J Urol. 1990; 66: 393-397
        • Ito R
        • Ishii M
        • Yamashita S
        • et al.
        Anti-prostatic hypertrophic action of cernitin pollen extract (Cernilton).
        Pharmacometrics. 1986; 31: 1-11
        • Buck AC
        • Cox R
        • Rees RWM
        • et al.
        Treatment of outflow tract obstruction due to benign prostatic hyperplasia with pollen extract, Cernilton. A double-blind, placebo-controlled study.
        Br J Urol. 1990; 66: 398-404
        • Boyarsky S
        • Jones G
        • Paulson DF
        • et al.
        A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostatic hypertrophy.
        Trans Am Assoc Genitourin Surg. 1977; 68: 29-32
        • Barry MJ
        • Mulley AG
        • Fowler FD
        • et al.
        Watchful waiting vs immediate transurethral resection for symptomatic prostatism.
        JAMA. 1988; 259: 3010-3017
        • Yasumoto R
        • Wada S
        • Kiyota A
        • et al.
        Hyperthermic treatment in patients with benign prostatic hypertrophy.
        Jpn J Urol. 1991; 82: 196-203
        • Yasumoto R
        • Yoshihara H
        • Kawashima H
        • et al.
        The use of a metallic stent in 32 patients with benign prostatic hypertrophy.
        Jpn J Urol. 1992; 83 (Preliminary results and 3 months of follow-up): 473-482
        • Horii A
        • Kyo M
        • Yasumoto R
        • et al.
        Transurethral balloon dilatation of the prostate: Initial results, indication and complication.
        Acta Urol Jpn. 1991; 37: 1455-1461
        • Kogawa T
        • Yanagiya H
        • Takashima T
        • et al.
        Clinical evaluation of the long-term treatment with chlormadinone acetate on patients with benign prostatic hypertrophy.
        Acta Urol Jpn. 1993; 39: 281-287
        • Kirby RS
        • Coppinger SW
        • Corcoran MO
        • et al.
        Prazosin in the treatment of prostatic obstruction: A placebo controlled study.
        Br J Urol. 1987; 60: 136-142
        • Vermeulen A
        • Giagulli VA
        • De Schepper P
        • et al.
        Hormonal effects of 5α-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.
        Eur Urol. 1991; 20: 82-86